Learn about Ureaplasma infection diagnosis, including clinical documentation, medical coding (ICD-10 codes like N76.0, A59.8), laboratory testing, and treatment. Find information on Ureaplasma urealyticum and Ureaplasma parvum infections, symptoms, and healthcare guidelines for accurate diagnosis and patient care. This resource covers essential information for healthcare professionals, clinicians, and medical coders.
Also known as
Other urogenital infections
This code encompasses various urogenital infections not classified elsewhere.
Urethritis, unspecified
Inflammation of the urethra without specifying the cause.
Other specified urethritis
Urethritis caused by an organism other than gonococcus or chlamydia.
Other bacterial agents as the cause of diseases classified elsewhere
This code can be used as a secondary code to specify Ureaplasma as the cause.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the Ureaplasma infection urogenital?
Yes
Is it urethritis?
No
Is it a respiratory infection?
When to use each related code
| Description |
|---|
| Ureaplasma Infection |
| Mycoplasma genitalium |
| Chlamydia trachomatis |
Coding Ureaplasma infection without specifying the affected site (e.g., urethra, cervix) leads to inaccurate data and potential claim denials. Use specific ICD-10 codes like A59.0 for urogenital infections.
Lack of proper clinical documentation to support the diagnosis of Ureaplasma infection poses audit risks. Ensure documentation clearly links symptoms, lab results, and diagnosis for accurate coding.
Incorrectly coding comorbidities alongside Ureaplasma infection without documented clinical evidence can lead to inflated reimbursement and compliance violations. Validate associated conditions.
Q: What are the most reliable diagnostic tests for differentiating Ureaplasma urealyticum and Ureaplasma parvum in symptomatic patients, and what are the implications for targeted antibiotic therapy?
A: Differentiating *Ureaplasma urealyticum* and *Ureaplasma parvum* is crucial for targeted antibiotic therapy due to varying antibiotic sensitivities. While traditional culture methods can distinguish species, molecular methods like PCR are becoming increasingly preferred due to their higher sensitivity and specificity. PCR assays can identify specific genetic markers unique to each species, enabling accurate diagnosis even in low bacterial loads. This information then informs antibiotic selection, as *U. urealyticum* tends to show greater resistance to tetracyclines compared to *U. parvum*. Accurate species identification helps avoid treatment failure and the development of antibiotic resistance. Explore how PCR testing can enhance your Ureaplasma diagnostic capabilities and improve patient outcomes. Consider implementing molecular diagnostics in your practice for more precise Ureaplasma species identification.
Q: How can I effectively manage recurrent Ureaplasma infections in women, considering factors like biofilm formation and the impact on reproductive health?
A: Recurrent Ureaplasma infections in women present a clinical challenge, often linked to biofilm formation and potential adverse effects on reproductive health, including pregnancy complications. Biofilms protect Ureaplasma from antibiotics and the host immune response, contributing to treatment failure and recurrence. Management strategies include longer antibiotic courses, combination therapy (e.g., doxycycline with azithromycin or moxifloxacin), and adjunctive therapies targeting biofilms, such as D-amino acids. Additionally, evaluating and addressing underlying factors that predispose to recurrence, such as sexual health practices and hygiene, is critical. Learn more about biofilm-disrupting strategies and the latest recommendations for managing recurrent Ureaplasma infections to enhance your patient care. Consider implementing a multi-faceted approach that addresses both the infection and the contributing factors to effectively manage recurrence and minimize the impact on reproductive health.
Patient presents with symptoms suggestive of a Ureaplasma infection. Presenting complaints may include urethritis, dysuria, urinary frequency, or pelvic pain in women. In men, symptoms can manifest as urethral discharge or discomfort. Asymptomatic Ureaplasma colonization is also possible and should be considered, especially in the context of pregnancy complications or infertility. Differential diagnoses include Chlamydia trachomatis infection, Mycoplasma genitalium infection, bacterial vaginosis, and other sexually transmitted infections. Diagnostic testing performed includes a nucleic acid amplification test (NAAT) from a urine sample or a urethral swab for men, and a vaginal or endocervical swab for women. Positive Ureaplasma urealyticum or Ureaplasma parvum NAAT confirms the diagnosis. Microscopy and culture are not routinely recommended due to lower sensitivity and specificity compared to NAAT. Treatment is indicated for symptomatic patients and those at risk of complications, such as pregnant women. Recommended treatment regimens include doxycycline, azithromycin, or erythromycin, with consideration for antibiotic susceptibility testing in cases of treatment failure. Patient education regarding safe sex practices, partner notification, and the importance of completing the full course of antibiotics was provided. Follow-up testing may be considered in certain cases, particularly for pregnant women or those with recurrent symptoms. This diagnosis is coded as A59.8, Other sexually transmitted diseases, not elsewhere classified, in the ICD-10-CM system. Medical billing will reflect the appropriate evaluation and management codes based on the complexity of the visit, as well as the specific laboratory tests performed.